Beating Cancer Precision Immunotherapy
Beating cancer with precision immunotherapy is a goal for many cancer researchers. For the first time, a drug has been FDA-approved for cancer based on disease genetics rather than type. Developed from 30 years of basic research at Johns Hopkins and its Bloomberg~Kimmel Institute, pembroluzimab now can be used for colon, pancreatic, stomach, ovarian and other cancers if genetic testing reveals defects in so-called mismatch repair genes. Drs. Bert Vogelstein and Dung Le describe this research and its potential impact for people with cancer. Learn more about immunotherapy at http://www.hopkinsmedicine.org/kimmel_cancer_center/centers/bloomberg_kimmel_institute_for_cancer_immunotherapy/index.html